OpenNCT05669846⚑ Report an issue with this listing

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Open to all qualified participants

Phase

PHASE2

Enrollment

26 (est.)

Age range

18 Years to —

Sex

ALL

Summary

This study evaluates whether Healthy Donor Fecal Microbiota Transplant (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 positive NSCLC, given alongside pembrolizumab.

Conditions studied

Non Small Cell Lung Cancer

Study locations

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania

Amy Rose, RN, BSN, CONTACT

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Summary

Conditions studied

Sponsors

Study locations